today in Company's portfolio there are 6 combined medicinal drugs without any
analogues available. Area of use: gynecology, dermatology, otorhinolaryngology, cardiology, elimination of flu and cold symptoms, fungal nail infections
one of the fields is the creation of quasi-original preparations: improved
remedy compounds based on known molecules but in new combinations, drug forms, dosages; or with the
intention of new application methods
More than 100 remedy items
under development and registration, including original combined innovative
preparations and generics
Eighteen patents for inventions and useful models
new drug forms, components combinations, ways of active agents supply in the
14 PhDs employed in the Company
of Chemistry, Medicine, Pharmaceuticals, Technology, Chemistry and Biology. More than a
half of them are in the Department of Product Portfolio Management, where products are created and
Science and R&D
WERTEKS owns the modern production complex and the own Research and
Development Centre for product development.
The Department of Product Portfolio Management includes the
Development Service, the Science Service, Pharmacology and Clinical Studies Office, and many other
subdivisions necessary to form the range of products.
The up-to-date equipment of laboratories allows to perform synthesis
of new substances and do analytical and bio-chemical research.
Range of Products
We produce remedies in highly-demanded socially-important therapeutic
fields, main of them being – cardiology, women's health, dermatology, otorhinolaryngology,
neurology, and others. In these areas we have created a modern portfolio of branded products, with
the elements of originality as well. Company's generics cover almost all therapeutic groups
In May 2016 Company signed the agreement on the scientific collaboration with
Almazov National Medical Research Centre of the Russian Ministry of Health. It is on the
development and performance of pre-clinical, clinical, pharmaceutical and economic research of
In 2019 WERTEKS signed a contract on scientific cooperation with Almazov National Medical Research Centre of the Ministry of Health of Russia for the development of cardiac drugs that have no analogues in the Russian market.